Company: Boston Scientific ($BSX)
Headquarters: Natick, MA
R&D budget 2012: $889 million
The bottom line: For the past three years, Boston Scientific's research budget has been in steady decline. 2012's $889 million R&D budget is a step down from $895 million in 2011 and $939 million in 2010. Still, the figure remains about 10% of the company's net sales annually. Why the drop? Boston Scientific overall has struggled. And the company has worked for a few years now to slash costs, boost efficiency and restructure R&D and other departments in order to "enhance our overall efficiency and effectiveness," Boston Scientific explains in its 10k regulatory filing. Its research and development efforts have included a focus on next-generation stents and defibrillators, a target of newer areas including neuromodulation to treat pain, and development work on devices such as its Watchman left appendage closure device for patients with nonvalvular atrial fibrillation.
Boston Scientific calms skeptics with Watchman results
Boston Scientific reaches into Japan with spinal deal